SCHEDULE: Armistice Capital Discloses 6.77% Stake in Verrica
Beneficial Ownership Disclosure
Armistice Capital and Steven Boyd have reported a 6.77% beneficial ownership stake in Verrica Pharmaceuticals Inc., holding 639,193 shares.
Summary
- Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 639,193 shares of Verrica Pharmaceuticals Inc. Common Stock.
- This ownership represents 6.77% of the company's outstanding common stock.
- The percentage is based on 9,445,768 shares outstanding as of August 5, 2025, as reported in the issuer's 10-Q filed on August 12, 2025.
- Armistice Capital, LLC, as the investment manager, and Steven Boyd, as its managing member, share voting and dispositive power over all 639,193 shares.
- The shares are held by Armistice Capital Master Fund Ltd., an investment advisory client of Armistice Capital, LLC.
- The acquisition of these securities was made in the ordinary course of business and not for the purpose of changing or influencing the control of Verrica Pharmaceuticals Inc.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects.
Positives
- A significant institutional investor, Armistice Capital, maintains a 6.77% stake in Verrica Pharmaceuticals Inc., which can be interpreted as a signal of continued confidence in the company's long-term prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Verrica Pharmaceuticals Inc.'s future performance or outlook.
Industry Context
This filing reflects an institutional investor's position in a pharmaceutical company, a common occurrence in the biotech and healthcare sectors where specialized funds often take significant stakes based on drug development pipelines or market potential. It does not provide broader industry trend analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Statement of Intent | The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer. | 2025-09-30 | This statement indicates a passive investment strategy, suggesting the investors do not intend to engage in activism or seek control of Verrica Pharmaceuticals Inc. at this time. |
Stakeholder Impact
- Shareholders may view the continued significant stake by Armistice Capital as a positive signal of institutional confidence in Verrica Pharmaceuticals Inc.
Key Dates
| Date | Description |
|---|---|
| 2025-08-05 | Date of shares outstanding calculation (9,445,768 shares) as per issuer's 10-Q. |
| 2025-08-12 | Date issuer's 10-Q was filed with the SEC. |
| 2025-09-30 | Date of event which required the filing of this statement (ownership threshold met or changed). |
| 2025-11-14 | Date the Schedule 13G/A filing was signed. |
Keywords
Verrica Pharmaceuticals, Armistice Capital, Steven Boyd, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.